` IDT (IDT Australia Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

IDT
vs
S&P/ASX 300

Over the past 12 months, IDT has underperformed S&P/ASX 300, delivering a return of -12% compared to the S&P/ASX 300's 10% growth.

Stocks Performance
IDT vs S&P/ASX 300

Loading
IDT
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
IDT vs S&P/ASX 300

Loading
IDT
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
IDT vs S&P/ASX 300

Loading
IDT
S&P/ASX 300
Add Stock

Competitors Performance
IDT Australia Ltd vs Peers

S&P/ASX 300
IDT
LLY
JNJ
NOVO B
ROG
Add Stock

IDT Australia Ltd
Glance View

Market Cap
39.5m AUD
Industry
Pharmaceuticals

IDT Australia Ltd. produces, develops and supplies pharmaceutical products. The company is headquartered in Melbourne, Victoria. The firm is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. The firm specializes in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging and pharmacy services. The company provides services for new drug development and scale-up, commercial active drug manufacture as well as a various oral and injectable finished drug dose forms. Its sterile manufacturing suite is designed to liquid fill and lyophilise a range of sterile pharmaceutical and biopharmaceutical drug products. Its current goods manufacturing practices (cGMP) facilities manufactures a range of medicinal cannabis products for local and international markets.

IDT Intrinsic Value
0.186 AUD
Undervaluation 51%
Intrinsic Value
Price
Back to Top